MLchartDataset catalogue

Opdualag

Term · Oncology and biomedicine · MLC-T-ONC-006094

A combination of nivolumab and relatlimab used to treat adults and children aged 12 years or older with melanoma that has spread or cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Opdualag binds to the proteins PD-1 and LAG-3, which are found on T cells (a type of immune cell). Blocking these proteins may help the immune system kill cancer cells. The combination of nivolumab and relatlimab may work better than either drug alone. Opdualag is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called nivolumab and relatlimab.

Table 1. Record
IdentifierMLC-T-ONC-006094
FieldOncology and biomedicine
Synonymsnivolumab and relatlimab
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-006094",
  "term": "Opdualag",
  "field": "Oncology and biomedicine",
  "definition": "A combination of nivolumab and relatlimab used to treat adults and children aged 12 years or older with melanoma that has spread or cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Opdualag binds to the proteins PD-1 and LAG-3, which are found on T cells (a type of immune cell). Blocking these proteins may help the immune system kill cancer cells. The combination of nivolumab and relatlimab may work better than either drug alone. Opdualag is a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called nivolumab and relatlimab.",
  "synonyms": [
    "nivolumab and relatlimab"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/opdualag/"
}

Record 12,259 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.